CIA
TGTX icon

Concurrent Investment Advisors’s TG Therapeutics TGTX Stock Holding History

Concurrent Investment Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22M Buy
22,143
+15,667
+242% +$641K 0.01% 920
2026
Q1 		$215K Buy
+6,476
New +$193K ﹤0.01% 1710

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Concurrent Investment Advisors's TGTX Position: Q2 2026 in Review

Concurrent Investment Advisors increased its TG Therapeutics (TGTX) stake by 242% in Q2 2026, buying an estimated $641K and bringing the position to 22,143 shares worth $1.22M. The position accounts for 0.01% of the portfolio, ranked #920.

Concurrent Investment Advisors first reported a position in TGTX in Q1 2026 and has held it in 2 quarters since. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Concurrent Investment Advisors held 22,143 shares of TG Therapeutics worth $1.22M as of Q2 2026.
  • Concurrent Investment Advisors bought 15,667 TG Therapeutics shares in Q2 2026, an estimated $641K.
  • TG Therapeutics made up 0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #920 holding.
  • Concurrent Investment Advisors first reported a position in TG Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.